FDA Accepts Application for Genentech's Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)

Source :: Plus Company Updates. July 29, 2021
Publication Year :: 2021
Abstract: SOUTH SAN FRANCISCO: GENENTECH has issued the following news release: Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug [...]

Subjects :: United States. Food and Drug Administration
Biological products industry -- Physiological aspects
Diabetic retinopathy -- Care and treatment
Dropsy -- Care and treatment
Macular degeneration -- Care and treatment
Edema -- Care and treatment
General interest
News, opinion and commentary

Tools